Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence. | Int J Mol Sci | 2026 | 41752108 | PubTator, text mining | PubMed |
| Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes. | Int J Mol Sci | 2026 | 41752040 | PubTator, text mining | PubMed |
| NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review. | Int J Mol Sci | 2026 | 41751981 | PubTator, text mining | PubMed |
| In Vivo CAR-T Therapies-A New Era of Programmable Immunity. | Int J Mol Sci | 2026 | 41751878 | PubTator, text mining | PubMed |
| Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy. | Cancers (Basel) | 2026 | 41749871 | PubTator, text mining | PubMed |
| Targeting Biliary Tract Cancers with Antibody-Drug Conjugates: Advances in Molecular Targets and Rational Combinations. | Cancers (Basel) | 2026 | 41749852 | PubTator, text mining | PubMed |
Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC). | Curr Oncol | 2026 | 41744884 | PubTator, text mining | PubMed |
| Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025. | Curr Oncol | 2026 | 41744870 | PubTator, text mining | PubMed |
| Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma. | Curr Oncol | 2026 | 41744867 | PubTator, text mining | PubMed |
| Trop2-Based Antibody-Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy. | Curr Oncol | 2026 | 41744856 | PubTator, text mining | PubMed |
| Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer. | Biology (Basel) | 2026 | 41744665 | PubTator, text mining | PubMed |
| Unlocking the "undruggable": current landscape and emerging frontiers in lysosomal receptor-mediated protein degradation. | Drug Deliv | 2026 | 41742445 | PubTator, text mining | PubMed |
| Cell-surface targets for prostate cancer therapeutics. | Urol Oncol | 2026 | 41741268 | PubTator, text mining | PubMed |
| Real-World Outcomes and Safety of PD-1 Blockade Rechallenge Strategies After Prior Immunotherapy in Advanced NSCLC: A Retrospective Cohort Study. | Drug Des Devel Ther | 2026 | 41737987 | PubTator, text mining | PubMed |
| A cell atlas of multiple liver organoids and the fetal liver based on scRNA-seq. | iScience | 2026 | 41736863 | PubTator, text mining | PubMed |
| What practicing pathologists and oncologists should know about the new computational pathology-based companion diagnostic tools. | J Pathol | 2026 | 41736658 | PubTator, text mining | PubMed |
| From hPSCs to MSCs: differentiation strategies, pathways, and the emergence of common regulatory networks. | Cell Mol Biol Lett | 2026 | 41735837 | PubTator, text mining | PubMed |
| Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment. | J Immunother Cancer | 2026 | 41734999 | PubTator, text mining | PubMed |
| The path forward for T cell engagers in patients with prostate cancer. | J Immunother Cancer | 2026 | 41734994 | PubTator, text mining | PubMed |
| Immune Doublet Checkpoint Inhibition in EGFR-Mutated NSCLC: A Fire That Fails to Illuminate the Orchard. | JTO Clin Res Rep | 2026 | 41732443 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=14